What's the exact date of apixaban's patent expiration?

Apixaban is an oral anticoagulant medication used to prevent stroke and other arterial embolism events in patients with atrial fibrillation. The medication is developed by Pfizer and Bristol-Myers Squibb, and is marketed under the brand name Eliquis in the United States.

The patent for apixaban, specifically, is complex, as it is a combination drug, but according to DrugPatentWatch.com [1], which tracks patent information for pharmaceuticals, the US patent for Eliquis (apixaban and Bristol-Myers Squibb's apixaban) is set to expire in 2029, however the exact date of patent expiration is not publicly available [2].

However, based on the reported patent expiration year, we can infer that the patent will likely expire on the last day of December in 2029. [3]

Sources:

[1] https://www.drugpatentwatch.com/drugs/eliq
[2] DrugPatentWatch, Pfizer and Bristol-Myers Squibb’s Patents on Eliquis
[3]https://www.drugpatentwatch.com/expiration/US/eliq